Sugi Predict

Sugi Predict / Compounds / SCHEMBL295564

SCHEMBL295564

SCHEMBL295564

CN(C)c1ccc(S(=O)(=O)Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.61
▸ ALOX15 P16050 4/20 0.61
▸ HSD17B10 Q99714 3/20 0.61
▸ KDM4E B2RXH2 1/20 0.61
▸ HPGD P15428 1/20 0.61
▸ TSHR P16473 3/20 0.52
▸ CA2 P00918 6/20 0.50
▸ CA9 Q16790 4/20 0.50
▸ TDP1 Q9NUW8 3/20 0.50
▸ CA12 O43570 3/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ POLB P06746 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ CA1 P00915 5/20 0.48
▸ CA4 P22748 1/20 0.48
▸ LMNA P02545 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7834724 0.92 ALDH1A1 (0.58) ALDH1A1ALOX15HSD17B10KDM4EHPGD
SCHEMBL42344 0.88 NPC1 (0.69) ALDH1A1ALOX15HSD17B10KDM4EHPGD
SCHEMBL42343 0.88 NPC1 (0.69) ALDH1A1ALOX15HSD17B10KDM4EHPGD
SCHEMBL26015294 0.88 ALDH1A1 (0.54) ALDH1A1ALOX15HSD17B10KDM4EHPGD
SCHEMBL22012448 0.80 ALDH1A1 (0.43) ALDH1A1ALOX15HSD17B10KDM4EHPGD
SCHEMBL3066016 0.80 MAPT (0.47) ALDH1A1ALOX15HSD17B10KDM4EHPGD
SCHEMBL4575039 0.80 ALDH1A1 (0.79) ALDH1A1ALOX15HSD17B10KDM4EHPGD
SCHEMBL2015756 0.80 NSD2 (0.47) ALDH1A1ALOX15HSD17B10KDM4EHPGD
SCHEMBL651902 0.79 ALDH1A1 (0.71) ALDH1A1HSD17B10TSHRCA2CA9
SCHEMBL2026589 0.78 ALDH1A1 (0.57) ALDH1A1ALOX15HSD17B10KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111244296-B Quantum dot light-emitting diode and preparation method thereof TCL科技集团股份有限公司 2021-05-18 — — CN claimed
CN-111244296-A Quantum dot light-emitting diode and preparation method thereof TCL集团股份有限公司 2020-06-05 — — CN claimed
CN-111234802-A Preparation method of quantum dots TCL集团股份有限公司 2020-06-05 — — CN claimed
CN-111234804-A Preparation method of quantum dots TCL集团股份有限公司 2020-06-05 — — CN claimed
WO-2026104679-A1 NOVEL SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2026-05-21 — — WO disclosed
WO-2026104681-A1 NEW SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2026-05-21 — — WO disclosed
WO-2026104680-A1 NOVEL SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2026-05-21 — — WO disclosed
US-12612384-B2 Heterocyclic CYP4A inhibitor compounds and compositions thereof MBD Co., Ltd. (KR) 2026-04-28 — — US disclosed
US-12600711-B2 Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors KEZAR LIFE SCIENCES, INC. (US) 2026-04-14 — — US disclosed
US-12479821-B2 Quinoline compound and use thereof MBD Co., Ltd. (KR) 2025-11-25 — — US disclosed
US-20240287032-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF MBD Co., Ltd. (KR) 2024-08-29 — — US disclosed
CN-112262129-B Triazacyclododecanesulfonamide (\"TCD\") based protein secretion inhibitors 科智生命科学公司 2024-05-14 — — CN disclosed
US-5376497-A Good sensitivity, rate of residual film and resolution NIPPON ZEON CO., LTD. (JP) 1994-12-27 — — US disclosed
US-5338755-A Have affinity for vasopressin and ocytocin receptors; intermediates for drugs that act on central nervous system ELF SANOFI (FR) 1994-08-16 — — US disclosed
US-5164514-A Antispasmodics ROUSSEL UCLAF (FR) 1992-11-17 — — US disclosed
EP-0510983-A1 Positive resist composition NIPPON ZEON CO., LTD. (JP) 1992-10-28 — — EP disclosed
US-5081130-A Antispasmodic agents ROUSSEL UCLAF (FR) 1992-01-14 — — US disclosed
US-5041436-A 1-arylsulphonyl-2-piperidinone derivatives, process and intermediates for the preparation thereof, their application as antispasmodics and compositions containing them ROUSSEL UCLAF (FR) 1991-08-20 — — US disclosed
US-4990531-A Antispasmodic agents ROUSSEL UCLAF (FR) 1991-02-05 — — US disclosed
US-3956385-A REACTING SULFONYLHALIDE WITH 2-CHLORO-ETHYLAMINE SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1976-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287032-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF CYP4B1, CYP4A11, CYP3A4 ALDH1A1 268/4885ALOX15 1616/4885HSD17B10 85/4885
US-12479821-B2 Quinoline compound and use thereof CYP4A11, CYP7A1, CYP4B1 ALDH1A1 647/4885ALOX15 812/4885HSD17B10 65/4885
US-12612384-B2 Heterocyclic CYP4A inhibitor compounds and compositions thereof CYP4A11, CYP4B1, CYP4A22 ALDH1A1 217/4885ALOX15 954/4885HSD17B10 65/4885
US-12600711-B2 Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors CD274, CD40, ICOS ALDH1A1 4237/4885ALOX15 2482/4885HSD17B10 2946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.